Thymalin
- Category
- Immune & Defense
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
A thymic peptide extract marketed to restore immune function and normalize T-cell balance in aging adults. Evidence is low confidence throughout: claims of reduced mortality, extended lifespan, and better severe COVID-19 outcomes rest on small, older, or animal studies, not robust human trials. Western safety data is limited and most supply is unregulated research-grade product of uncertain purity. Not an approved drug in the US.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Note: Thymalin is not a single peptide but a polypeptide complex extracted from calf thymus glands. It contains a mixture of short peptides (2-8 amino acids) including EW, KE, and EDP. It is classified as a "cytomedin" bioregulator in the Khavinson peptide system.
Thymalin is a mixture of small peptides extracted from calf thymus glands, developed by Professor Vladimir Khavinson beginning in the 1970s and approved as a pharmaceutical immunomodulator in the USSR in 1982. The thymus is the organ responsible for training T-cells — the immune system's front-line defenders — and it shrinks dramatically with age, weakening immunity. Thymalin provides the signaling peptides from young thymus tissue to help compensate for this age-related decline. It remains an approved pharmaceutical in the Russian Federation.
How it works in the body
An extract of thymic peptides that restores thymus function. It promotes the differentiation of bone marrow stem cells into mature T lymphocytes, normalizes the CD4/CD8 ratio, and enhances both innate and adaptive immunity. It also modulates neuroendocrine function through thymus-hypothalamus cross-talk.
Research overview
Thymalin works by supplying the body with thymic peptide factors that activate T-cell development, improve the ratio of immune cell types, and stimulate the body's infection-fighting and tissue-repair processes. Its most notable finding comes from a study of 266 elderly patients where annual Thymalin treatment reduced mortality by 2-fold over 6-8 years, and the combination with a pineal peptide (Epithalamin) reduced mortality by 4.1-fold. More recently, Thymalin was shown to boost CD28+ T-cell production 6.8-fold from human stem cells, with applications explored in severe COVID-19 patients. Animal studies in mice showed extended survival and reduced spontaneous tumor rates. The research spans 40+ years with dozens of publications, though the major limitation is that the landmark human study was not a randomized double-blind trial by Western standards, and no independent replication outside Russian institutions has been published.
Who researches Thymalin?
Commonly researched by
People exploring tissue repair and injury recovery
Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.
People researching immune system support
Studied for immune modulation, antiviral, or antimicrobial properties.
People researching longevity and anti-aging interventions
Studied for effects on aging pathways, cellular health, or lifespan extension.
Important considerations for
Those with Organ transplant recipients
HighThymic peptide immune stimulation may counteract immunosuppressive therapy.
Those with Active autoimmune disease
ModerateImmune modulation via thymic peptides may exacerbate autoimmune conditions.
Those who are pregnant or breastfeeding
AbsoluteNo reproductive safety data.
Safety & interactions
Do not use if
Organ transplant recipients
HighThymic peptide immune stimulation may counteract immunosuppressive therapy.
Active autoimmune disease
ModerateImmune modulation via thymic peptides may exacerbate autoimmune conditions.
General cautions
Pregnancy
AbsoluteNo reproductive safety data.
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(7)
Rated by level of concern
Potential interference with immunosuppressive therapy
TheoreticalMechanistic inference from PMID 33237528; no published clinical reports
Limited Western safety data and lack of independent validation
HighFDA - no approved product; PubMed authorship pattern across PMIDs 12577695, 14523363, 33575961, 36169363
Theoretical risk of immune overstimulation or autoimmunity
TheoreticalClass-based mechanistic inference; no supporting case literature
Caution with active thymic tumors or thymoma
TheoreticalPMID 29797130 (Bull Exp Biol Med 2018); otherwise mechanistic
Unregulated product quality from research-grade sources
HighProduct class assessment - no FDA/EMA monograph exists
Contraindicated in pregnancy, lactation, and specific populations
ModerateRussian product labeling; no published reproductive-toxicity studies
Mild injection site reactions
LowPMID 33575961; Russian product labeling
Interaction summary(8)
Rated by direction with this peptide
Immunosuppressants / anti-rejection therapy (tacrolimus, cyclosporine, mycophenolate, azathioprine)
CautionTheoreticalThymalin's T-lymphocyte maturation effect directly opposes the intended pharmacology, so co-use in transplant or autoimmune patients could in principle erode immunosuppressive control, though no rejection or flare cases have been published.
Mechanistic inference from PMID 33237528; no clinical reports
Immune checkpoint inhibitors (anti-PD-1 / anti-PD-L1 / anti-CTLA-4)
CautionTheoreticalBoth act to expand and activate T-cell responses, raising an additive risk of immune-related adverse events; no combination data exist in humans or animals - this is a purely mechanistic caution.
Class mechanism; no published combination studies
Cytotoxic chemotherapy
SynergisticLowIn mouse tumor models thymalin added to chemotherapy increased tumor growth inhibition and survival, consistent with its long-standing Russian use as an adjunct to mitigate chemotherapy-induced immunosuppression, but this has not been confirmed in controlled human oncology trials.
PMID 3686911; PMID 29797130
Tocilizumab (IL-6 receptor blockade)
SynergisticLowSevere COVID-19 cohorts compared and combined thymalin with tocilizumab, reporting faster normalization of IL-6, CRP, D-dimer and coagulation morphology without a described safety signal, though the studies were open-label and non-randomized.
PMID 36169363; PMID 33575961
Systemic corticosteroids (e.g. dexamethasone, prednisolone)
CautionTheoreticalGlucocorticoids are thymolytic and lymphopenia-inducing, so they plausibly blunt thymalin's thymopoietic effect - a pharmacodynamic opposition rather than a documented adverse interaction; notably, thymalin was administered alongside steroid-containing COVID protocols without reported harm.
Mechanistic; context from PMID 33575961
Other thymic peptides (thymosin alpha-1, thymogen/Glu-Trp, thymopentin)
CautionTheoreticalOverlapping thymomimetic mechanisms mean using them together offers no demonstrated additive benefit while adding to any immunostimulatory risk; thymalin already contains the active KE and EW dipeptide fragments.
PMID 37686182; PMID 11707921
Anticoagulants / antiplatelet agents (heparin, DOACs)
NeutralTheoreticalThymalin accelerated D-dimer and coagulation-marker normalization in severe COVID-19 patients who were also anticoagulated, but no bleeding signal or direct effect on clotting-factor pharmacology was reported - monitoring rather than avoidance is the reasonable posture.
PMID 36169363; PMID 33575961
Vaccines (inactivated and mRNA)
NeutralTheoreticalAn immunomodulator that matures T-lymphocytes could theoretically alter vaccine responsiveness in either direction, but no human immunogenicity data with thymalin co-administration have been published.
No published studies; mechanistic only
Known risks(7)
Potential interference with immunosuppressive therapy
HighThymalin is a potent immune activator that stimulates T-cell differentiation, proliferation, and function. It may counteract the effects of immunosuppressive drugs such as tacrolimus, cyclosporine, and sirolimus used in organ transplant recipients. Co-administration without specialist guidance could lead to graft rejection or destabilization of immunosuppressive regimens. Thymalin is contraindicated in organ transplant patients on immunosuppressants.
Limited Western safety data and lack of independent validation
ModerateDespite 40+ years of use in Russia, Thymalin safety data has not been organized into Western-standard pharmacovigilance databases. All published safety data originates from Khavinson-affiliated groups. No FDA review of safety has occurred. No independent, large-scale safety monitoring has been conducted outside Russia. Long-term risks in diverse populations remain poorly characterized by international standards.
Theoretical risk of immune overstimulation or autoimmunity
ModerateAs an immune stimulant that activates T-cell differentiation and proliferation, Thymalin could theoretically exacerbate autoimmune conditions or cause immune overstimulation in susceptible individuals. Patients with autoimmune diseases (rheumatoid arthritis, lupus, multiple sclerosis, Hashimoto's thyroiditis, etc.) should exercise extreme caution. No studies have specifically evaluated Thymalin safety in autoimmune populations.
Caution with active thymic tumors or thymoma
ModerateA thymoma-specific contraindication or tumor-growth risk is not established by the cited evidence. The Russian manufacturer's label includes persistent thymic dysfunction associated with thymus tumors among its indications; management requires specialist assessment. While animal studies show reduced spontaneous tumor incidence, this protective effect may not extend to thymus-specific neoplasms.
Unregulated product quality from research-grade sources
ModerateUnregulated Thymalin products sold online are not manufactured under pharmaceutical GMP standards and is not subject to FDA quality oversight. Purity, identity, sterility, and endotoxin levels may vary among unregulated products sold online. The original Russian pharmaceutical preparation is manufactured under Russian GMP standards but may not meet US/EU pharmaceutical manufacturing requirements.
Contraindicated in pregnancy, lactation, and specific populations
Moderate (specific populations)Pregnancy and breastfeeding are listed as contraindications. Thymalin's potent immunomodulatory and epigenetic gene-regulatory activity raises theoretical concerns about effects on fetal immune development. No reproductive or developmental safety studies have been published. People with weakened immune systems should ensure thymus-derived products are certified germ-free.
Mild injection site reactions
LowCommonly reported mild side effects include injection site pain, redness, or swelling, particularly with intramuscular administration. These are typically transient and self-resolving. Rare reports of restlessness or irritability have been noted, especially when combined with Epitalon.
Drug interactions(6)
Immunosuppressants (tacrolimus, cyclosporine, sirolimus)
Thymalin is a potent immunostimulant that activates T-cell differentiation and proliferation. It may directly counteract the therapeutic immunosuppression provided by transplant medications, potentially leading to graft rejection. This is the most clinically significant drug interaction. Concurrent use is contraindicated without specialist guidance.
Other thymic peptide preparations (T-activin, Thymactide, Thymogen, Thymoptin)
Thymalin should not be combined with drugs that have similar mechanisms of action without specialist oversight. Additive immunostimulatory effects could lead to excessive immune activation. Thymogen (EW dipeptide) is itself a component of Thymalin, so co-administration is redundant and potentially problematic.
Corticosteroids (prednisone, dexamethasone, hydrocortisone)
Corticosteroids suppress immune function and T-cell activity, while Thymalin stimulates them. The pharmacological effects may partially oppose each other. In the COVID-19 clinical study, Thymalin was used alongside standard therapy which may have included corticosteroids, suggesting potential clinical compatibility, but formal interaction studies have not been conducted.
Chemotherapy and radiotherapy agents
Thymalin has been studied as an adjunct to restore immune function after chemotherapy- and radiotherapy-induced immunosuppression and hematopoietic depression. Russian clinical practice includes Thymalin in post-chemo/radio recovery protocols. The interaction is considered beneficial rather than adverse in this context, but timing and dosing should be managed by an oncologist.
Other Khavinson peptide bioregulators (Epithalamin, Cortexin, Pinealon)
The 266-patient longevity study tested Thymalin with Epithalamin (pineal gland peptide), reporting a 2.5-fold mortality reduction (vs 2.0-2.1-fold for Thymalin alone). No formal interaction studies have been conducted.
Biologic immunomodulators (TNF inhibitors, IL-6 inhibitors, checkpoint inhibitors)
No studies have evaluated Thymalin in combination with modern biologic immunomodulators. Thymalin's T-cell stimulatory effects could theoretically interact with immune checkpoint inhibitors (nivolumab, pembrolizumab) or modify the effects of cytokine-targeted biologics. Caution is warranted; specialist guidance is essential.
Research & benefits
Evidence base
- Evidence Level
- Moderate
- Total Studies
- 20
- Human Studies
- 4
Thymalin has a more substantial clinical evidence base than most Khavinson bioregulators, owing to its pharmaceutical status in Russia since 1982 and the 40+ years of clinical application. The strongest evidence comes from the 266-patient elderly longevity study demonstrating 2.0-2.1-fold mortality reduction over 6-8 years (and 4.1-fold with combined annual treatment), and the COVID-19 study showing halved hospital mortality in severe elderly patients receiving Thymalin as adjunctive therapy. The listed rat and CBA-mouse lifespan studies tested synthetic peptides rather than Thymalin extract. The Glu-Trp rat study found similar mean lifespan, although the longest-lived animals survived longer and tumor incidence decreased. Mechanistic evidence is well-characterized: Thymalin stimulates hematopoietic stem cell differentiation into mature T-lymphocytes (6.8-fold CD28 increase), activates T-cell immunity, and regulates gene expression through direct DNA binding. Major limitations: the human longevity study was not an RCT, all research originates from Khavinson-affiliated groups, no independent Western replication exists, and no FDA-standard clinical trials have been conducted.
Researched for(6)
Rated by confidence in the evidence
Reduction of all-cause mortality in elderly patients via immune restoration
LowBased on one unblinded, non-randomized human cohort study, never independently replicated.
PMID 14523363 (Neuro Endocrinol Lett 2003); PMID 12577695 (Adv Gerontol 2002)
Stimulation of hematopoietic stem cell differentiation into mature T-lymphocytes
LowDemonstrated in one human cell-culture study only, with no in vivo confirmation yet.
PMID 33237528 (Bull Exp Biol Med 2020); PMID 33575961 (Stem Cell Rev Rep 2021)
Extended lifespan and reduced spontaneous carcinogenesis in animal models
LowConsistent rodent data from one research group, with modest effects on average lifespan.
PMID 11707921 (Glu-Trp, rats); PMID 3686911 (thymalin + chemotherapy, mice); PMID 12577695
Improved immune recovery and reduced mortality in severe COVID-19 patients
LowReported in a small randomized, single-blind trial and other clinical reports; independent replication remains needed.
PMID 33575961 (Stem Cell Rev Rep 2021); PMID 36169363 (Adv Gerontol 2022)
Geroprotective regulation of thymocyte differentiation, proliferation, and apoptosis
LowSupported by consistent animal and cell studies; human thymic effects remain unmeasured.
PMID 12577695 (Adv Gerontol 2002); PMID 29797130 (Bull Exp Biol Med 2018, thymus/tumor in vivo)
Epigenetic regulation of immune gene expression and gerontogene activity
SpeculativeBased on molecular modeling and in vitro cytokine data; direct DNA binding unproven.
PMID 37686182 (Int J Mol Sci 2023)
Benefits(6)
Reduction of all-cause mortality in elderly patients via immune restoration
Khavinson & Morozov 2003 (Neuroendocrinology Letters, PMID 14523363) — In 266 elderly and older patients followed for 6-8 years, Thymalin treatment (applied during the first 2-3 years) decreased mortality by 2.0-2.1-fold compared to control. The combination of Thymalin with Epithalamin decreased mortality by 2.5-fold, and annual treatment with both peptides for 6 years decreased mortality 4.1-fold. Health improvements included normalized cardiovascular, endocrine, immune, and nervous system function, plus a 2.0-2.4-fold decrease in acute respiratory disease incidence and reduced manifestations of ischemic heart disease, hypertension, osteoarthrosis, and osteoporosis.
Stimulation of hematopoietic stem cell differentiation into mature T-lymphocytes
Khavinson et al. 2020 (Bulletin of Experimental Biology and Medicine, PMID 33237528) — Thymalin reduced expression of CD44 (stem cell marker) and CD117 (intermediate differentiation marker) by 2-3 times and increased expression of CD28 (mature T-lymphocyte marker) by 6.8 times in human hematopoietic stem cell cultures, demonstrating that Thymalin stimulates differentiation of CD117+ cells into mature CD28+ T-lymphocytes. This mechanism is directly relevant to compensating for age-related thymic involution.
Extended lifespan and reduced spontaneous carcinogenesis in animal models
Anisimov et al. 2001 (Mechanisms of Ageing and Development, PMID 11163623) — In 50 female CBA mice treated with synthetic thymic dipeptide Lys-Glu monthly from age 6 months until natural death, treatment increased physical activity and decreased spontaneous lung adenoma incidence. Anisimov et al. 2000 (Biogerontology, PMID 11707921) — L-Glu-L-Trp dipeptide (isolated from Thymalin) slowed down aging and inhibited spontaneous carcinogenesis in female rats, with activation of T-cell differentiation and enhanced phagocytosis. Earlier work by Anisimov, Khavinson et al. showed thymus factors increased lifespan of young mice by 20% and middle-aged mice by 17%, with decreased overall tumor incidence.
Improved immune recovery and reduced mortality in severe COVID-19 patients
Khavinson et al. 2021 (Advances in Gerontology, PMC8654498) — In elderly patients with severe COVID-19, addition of Thymalin to standard therapy (n=36 vs n=44 control) resulted in more rapid clinical improvement, faster recovery from lymphopenia, and accelerated normalization of C-reactive protein, D-dimer, lymphocyte counts, and NK-cell numbers. Thymalin halved hospital mortality in older patients with severe COVID-19. Khavinson et al. 2021 (Stem Cell Reviews and Reports, PMID 33575961) — Review analyzing results and prospects of using Thymalin as an activator of hematopoietic stem cell differentiation in complex therapy for COVID-19 patients.
Geroprotective regulation of thymocyte differentiation, proliferation, and apoptosis
Lin'kova et al. 2011 (Bulletin of Experimental Biology and Medicine, PMID 22238759) — Study of peptidergic regulation of thymocyte differentiation, proliferation, and apoptosis during aging of the thymus. Peptide AB-9 exhibited complex geroprotective effects on thymocytes during aging, stimulating proliferative activity and differentiation while inhibiting apoptosis. Khavinson & Anisimov 2003 (Advances in Gerontology, PMID 12577695) — Review of geroprotective effects of Thymalin and Epithalamin demonstrating their ability to normalize basic functions of the human organism.
Epigenetic regulation of immune gene expression and gerontogene activity
Khavinson et al. 2021 (Biology Bulletin Reviews, PMC8365293) — Comprehensive review analyzing the molecular mechanisms of Thymalin and its component peptides (EW, KE, EDP). These peptides complementarily bind to specific DNA sequences and histone proteins, regulating expression of heat-shock proteins, cytokines, fibrinolysis system, gerontogenes, and proteins controlling immune cell differentiation, proliferation, and apoptosis. Provides the most detailed molecular-level explanation of Thymalin's biological activity.
Key studies(5)
Peptides of pineal gland and thymus prolong human life
Prospective clinical cohort study (human, elderly)266 elderly and older patients (Thymalin, Epithalamin, combined, and control groups)6-8 years follow-up; bioregulators applied during first 2-3 yearsKhavinson VKh, Morozov VG
Neuroendocrinology Letters
2003
Thymalin treatment decreased all-cause mortality by 2.0-2.1-fold, Epithalamin by 1.6-1.8-fold, and combined Thymalin+Epithalamin by 2.5-fold versus control. Annual treatment with both peptides for 6 years decreased mortality 4.1-fold. Bioregulators normalized cardiovascular, endocrine, immune, and nervous system function, decreased acute respiratory disease incidence 2.0-2.4-fold, and reduced manifestations of ischemic heart disease, hypertension, osteoarthrosis, and osteoporosis. The most comprehensive human longevity data for any Khavinson peptide bioregulator.
Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells
Experimental research (in vitro, human stem cells)Human hematopoietic stem cell culturesCell culture experimentKhavinson VKh, Linkova NS, Kvetnoy IM, Khavinson AV, Linkova YaN, Dyatlova AS
Bulletin of Experimental Biology and Medicine
2020
Thymalin reduced CD44 (stem cell marker) and CD117 (intermediate differentiation marker) expression by 2-3 times and increased CD28 (mature T-lymphocyte marker) expression by 6.8 times, demonstrating that Thymalin stimulates differentiation of CD117+ cells into mature CD28+ T-lymphocytes. This mechanism explains how Thymalin compensates for age-related thymic involution and provides the rationale for its application in immunosenescence and COVID-19.
Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats
Experimental animal study (lifetime, female rats)Female rats, lifetime follow-upLifetime (until natural death)Anisimov VN, Khavinson VKh, Morozov VG
Biogerontology
2000
The synthetic dipeptide L-Glu-L-Trp (isolated from Thymalin) slowed aging and inhibited spontaneous carcinogenesis in female rats. The dipeptide activated T-cell differentiation, T-cell recognition of peptide-MHC complexes, modulated intracellular cyclic nucleotide composition, and activated neutrophilic chemotaxis and phagocytosis. Results demonstrated immunomodulatory and geroprotective effects of the key active component of Thymalin.
Effect of synthetic thymic and pineal peptides on biomarkers of ageing, survival and spontaneous tumour incidence in female CBA mice
Experimental animal study (lifetime, CBA mice)50 female CBA mice (three groups: saline, Lys-Glu dipeptide, Ala-Glu-Asp-Gly tetrapeptide)From age 6 months until natural death (monthly 5-day courses)Anisimov VN, Khavinson VKh, Mikhalski AI, Yashin AI
Mechanisms of Ageing and Development
2001
Synthetic thymic dipeptide Lys-Glu (0.1 mcg/animal, monthly 5-day courses from age 6 months) did not significantly influence body weight or estrous function but increased physical activity and decreased spontaneous lung adenoma incidence in female CBA mice. The study provided evidence for the anticarcinogenic and geroprotective activity of synthetic thymic peptides across the full lifespan.
The Use of Thymalin for Immunocorrection and Molecular Aspects of Biological Activity
Comprehensive reviewN/A (review of 40+ years of research)N/A (review)Khavinson VKh, Linkova NS, Chalisova NI, Ivko OM
Biology Bulletin Reviews
2021
Comprehensive review analyzing Thymalin's molecular mechanisms: component peptides EW, KE, and EDP complementarily bind to specific DNA sequences and histone proteins, regulating gene expression of heat-shock proteins, cytokines, fibrinolysis system, gerontogenes, and proteins involved in immune cell differentiation, proliferation, and apoptosis. Concluded Thymalin and Thymogen have practically no side effects and may be effective in complex therapy for coronavirus infection COVID-19.
Regulation & availability
Why researchers look at it
A study of 266 elderly patients showed annual treatment reduced all-cause mortality 2-fold over 6-8 years, extending to 4.1-fold when combined with the pineal peptide Epithalamin — among the most striking human mortality data for any peptide in the longevity space. More recent work demonstrated a 6.8-fold increase in CD28+ T-cell production from human stem cells. The landmark study was not an RCT by Western standards and has never been independently replicated — if it were, the implications for aging medicine would be substantial.
- Estimated cost
- $40-100/mo (injection or oral)
- FDA status
- Not FDA-approved. FDA's February 7, 2024 warning letter identified US Chem Labs' Thymalin products as unapproved new drugs and misbranded drugs marketed for human use despite research-only labeling. The letter addressed unlawful marketing and interstate distribution, rather than a compounding-pharmacy inspection. No qualifying US bulk-compounding pathway was identified. In Russia, Thymalin holds full pharmaceutical approval as an immunomodulator since 1982 (USSR Ministry of Health Order No. 1108, Reg. No. 82/1108/8), and this authorization has been maintained by the Russian Ministry of Health through the present day. It is one of six Khavinson peptide preparations with pharmaceutical (not merely supplement) status in Russia.
- WADA status
- Thymalin is not named on the 2026 List. S0 accepts current governmental human-therapeutic approval from any country, including Russia. Confirm the exact preparation and current authorization with the relevant anti-doping authority.
- Prescribability
- Thymalin is a prescription thymus-extract medicine in Russia according to the manufacturer's medicinal label. It is prescribable as an approved pharmaceutical in the Russian Federation and some CIS countries, where it has been authorized by the Russian Ministry of Health as an immunomodulator since 1982. It is one of six Khavinson peptide bioregulators that hold pharmaceutical (not supplement) status in Russia, alongside Cortexin, Epithalamin, Samprost, Retinalamin, and Thymogen. In Russia, it is prescribed by physicians for immunodeficiency states, viral and bacterial infections, post-chemotherapy and post-radiotherapy immunosuppression, and as a geroprotector in elderly patients. It is not FDA-approved. No qualifying US bulk-compounding pathway was identified under sections 503A or 503B; a prescription or foreign approval does not by itself establish federal compounding eligibility.
- Availability
- Thymalin has broader availability than most Khavinson bioregulators because of its pharmaceutical status. It is an approved pharmaceutical in the Russian Federation (approved since 1982), supplied as a powder for injection; a Russian prescription preparation is documented by Samson-Med's medicinal label. Some international longevity clinics and functional medicine and anti-aging practitioners use Thymalin for immune restoration, particularly in elderly patients with immunosenescence, post-infection immune recovery, and comprehensive anti-aging programs. Thymalin is NOT available through US pharmacies, is not listed in any Western pharmacopeia, and cannot be obtained through standard US/EU prescription channels. Thymalin is not FDA-approved, and no qualifying US bulk-compounding pathway was identified. Overseas availability does not establish lawful US importation, dispensing, or compounding.
International status
EU
Not approved
US
Not approved
Russia
Used clinically (Khavinson bioregulator protocol)
Worldwide
Limited to Russian clinical use
Regulatory timeline(14)
- 1971Vladimir Khavinson begins research on peptide bioregulators as part of a Soviet military research program at the Military Medical Academy in Leningrad (St. Petersburg).
- 1974Thymalin polypeptide complex is first extracted from calf thymus at Khavinson's laboratory, establishing the foundation for thymic peptide bioregulation research.
- 1977-1982Preclinical and early clinical studies of Thymalin conducted under Soviet military and medical research programs, demonstrating immunomodulatory activity.
- 1982-11-10Thymalin receives pharmaceutical approval from the USSR Ministry of Health (Order No. 1008, Registration No. 82.1008.8) as an immunomodulator — one of the first Khavinson peptide bioregulators to achieve pharmaceutical status.
- 1980s-1990sThymogen (L-Glu-L-Trp dipeptide) is isolated from Thymalin via RP-HPLC, synthesized, and registered as a separate pharmaceutical. Extensive clinical use of Thymalin in Russian medicine for immunodeficiency, infections, and post-chemo/radiotherapy recovery.
- 1992St. Petersburg Institute of Bioregulation and Gerontology established as Khavinson's primary research center; Thymalin becomes central to the peptide bioregulation aging research program.
- 1995-2003Landmark 266-patient elderly longevity study conducted across St. Petersburg Institute of Bioregulation and Gerontology and Kiev Institute of Gerontology. Thymalin and Epithalamin administered during first 2-3 years, patients followed 6-8 years.
- 2001Anisimov & Khavinson publish CBA mouse and rat lifespan/carcinogenesis studies demonstrating extended survival and reduced tumors with synthetic thymic peptides (PMID 11163623, 11707921).
- 2003Khavinson & Morozov publish the landmark human longevity results showing 2.0-2.1-fold mortality reduction with Thymalin in Neuroendocrinology Letters (PMID 14523363).
- 2009Khavinson publishes '35-year research experience' review of peptide regulation of aging, summarizing the full trajectory from military research to clinical application (PMID 19902107).
- 2020Khavinson et al. demonstrate Thymalin activates differentiation of human hematopoietic stem cells into mature CD28+ T-lymphocytes (6.8-fold CD28 increase), published in Bulletin of Experimental Biology and Medicine (PMID 33237528).
- 2021Clinical application of Thymalin in severe COVID-19 elderly patients demonstrates halved hospital mortality and accelerated immune recovery (Advances in Gerontology, PMC8654498). Comprehensive molecular mechanism review published in Biology Bulletin Reviews (PMC8365293).
- 2024-02On February 7, 2024, FDA warned US Chem Labs about marketing and distributing unapproved and misbranded Thymalin products for human use.
- 2026-03Thymalin remains approved as a pharmaceutical in Russia, without FDA approval or formal clinical development in the US/EU.
Sources & FAQs
Research sources(15)
- Khavinson & Morozov 2003 — Peptides of pineal gland and thymus prolong human life (266-patient longevity study)
- Khavinson et al. 2020 — Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells
- Anisimov et al. 2001 — L-Glu-L-Trp slows aging and inhibits spontaneous carcinogenesis in rats
- Anisimov et al. 2001 — Synthetic thymic and pineal peptides, biomarkers of ageing, CBA mice
- Khavinson et al. 2021 — Thymalin for immunocorrection, molecular aspects of biological activity (review)
- Khavinson et al. 2021 — Thymalin regulates immune status in severe COVID-19 older patients
- Khavinson et al. 2021 — Results and prospects of using activator of HSC differentiation in COVID-19
- Lin'kova et al. 2011 — Peptidergic regulation of thymocyte differentiation during thymus aging
- Khavinson & Anisimov 2003 — Geroprotective effect of thymalin and epithalamin
- Khavinson et al. 2002 — Peptides and Ageing (review)
- Khavinson 2009 — Peptide regulation of aging: 35-year research experience
- Khavinson et al. 2003 — Peptide bioregulators: new class of geroprotectors (clinical results)
- FDA Warning Letter — US Chem Labs (Thymalin products), Feb 2024
- WADA 2026 Prohibited List
- Vladimir Khavinson — Wikipedia
Frequently asked questions(6)
What is the difference between Thymalin, Thymogen, and Thymosin Alpha-1?
Thymalin is a polypeptide complex extracted from calf thymus containing multiple bioactive peptide fractions. Thymogen (also called Thymagen or EW peptide) is a synthetic dipeptide (L-Glu-L-Trp) that was isolated from Thymalin as its key immunomodulatory component — it is a single, defined molecule and is registered as a separate pharmaceutical in Russia. Thymosin Alpha-1 (Zadaxin) is a completely different thymic peptide: a 28-amino-acid peptide originally isolated from Thymosin Fraction 5 by Allan Goldstein's group in the US. Thymosin Alpha-1 has undergone more extensive Western clinical development and was approved in several countries for hepatitis B. While all three are thymus-derived immune modulators, they differ in composition, mechanism, and regulatory status.
Is Thymalin safe? What are the side effects?
Thymalin has been used clinically in Russia for over 40 years and is described as 'practically non-toxic' in the published literature. The 2021 comprehensive review by Khavinson et al. (PMC8365293) states that 'Thymalin and Thymogen have practically no side effects.' The 266-patient elderly study over 6-8 years reported no significant adverse effects. However, this safety profile is based primarily on Russian clinical experience without Western-standard pharmacovigilance. Reported side effects are minimal and include mild injection site reactions and rare restlessness or irritability (particularly when combined with Epitalon). People with thymic tumors require specialist assessment; a thymoma-specific contraindication is not established. Thymalin should be avoided by those taking organ transplant immunosuppressants (it may counteract immunosuppression from tacrolimus or cyclosporine), during pregnancy or breastfeeding, and by those already taking other thymic peptide drugs (T-activin, thymactide, thymogen, thymoptin) without specialist guidance.
How does Thymalin relate to COVID-19 treatment?
In severe COVID-19, particularly in elderly patients, lymphopenia and suppression of T-cell immunity are key drivers of poor outcomes. Khavinson's group demonstrated that Thymalin stimulates differentiation of hematopoietic stem cells into mature CD28+ T-lymphocytes (6.8-fold increase in CD28 expression). In a clinical study of elderly patients with severe COVID-19, addition of Thymalin to standard therapy halved hospital mortality, accelerated recovery from lymphopenia, and normalized inflammatory markers (C-reactive protein, D-dimer, IL-6) faster than standard therapy alone. The publication describes a small randomized, single-blind, placebo-controlled trial. Its findings still need independent replication.
How does Thymalin work at the molecular level?
Thymalin's active peptide components (EW, KE, EDP) are small enough to cross cell and nuclear membranes and interact directly with DNA and histone proteins. The EW dipeptide specifically binds to the AACG nucleotide sequence in DNA. Through these epigenetic interactions, Thymalin regulates the expression of genes encoding heat-shock proteins, cytokines, fibrinolysis factors, gerontogenes (aging-related genes), and proteins involved in immune cell differentiation, proliferation, and apoptosis. At the cellular level, Thymalin activates T-cell differentiation, enhances T-cell recognition of peptide-MHC complexes, modulates intracellular cyclic nucleotide composition, and stimulates neutrophilic chemotaxis and phagocytosis.
Is the research on Thymalin credible?
Thymalin has a more substantial evidence base than most Khavinson bioregulators, with 40+ years of research, pharmaceutical approval in Russia since 1982, and publications in indexed journals including Neuroendocrinology Letters, Biogerontology, Mechanisms of Ageing and Development, Bulletin of Experimental Biology and Medicine, and Biology Bulletin Reviews. The 266-patient longevity study is one of the most significant human datasets in peptide bioregulation research. However, nearly all studies originate from Khavinson's group or affiliated Russian institutions. The older longevity evidence has important design limitations, but the 2021 COVID-19 publication describes a small randomized, single-blind, placebo-controlled trial. No independent replication by Western research groups has been published. The research is internally consistent but requires external validation.
What is the difference between injectable Thymalin and capsule bioregulators?
The original pharmaceutical Thymalin is a lyophilized powder for intramuscular or subcutaneous injection. Oral capsule products are also marketed as thymus peptide bioregulators (e.g., Vladonix, which is an oral capsule containing thymus-derived peptides). The injectable form delivers the full polypeptide complex directly into the bloodstream. The oral capsule forms rely on the claimed ability of ultrashort peptides (di- and tripeptides) to be absorbed intact by intestinal peptide transporters. The injectable form has more clinical evidence behind it, as the major studies (266-patient longevity study, COVID-19 study, animal studies) used injectable Thymalin.